TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo

Humanized Lewis-Y Specific Antibody Based Delivery ofSTAT3siRNA

(2011) Yuelong Ma et al.   ACS Chemical Biology

Elevated frequencies of leukemic myeloid and plasmacytoid dendritic cells in acute myeloid leukemia with the FLT3 internal tandem duplication

(2011) Mareike Rickmann et al.   ANNALS OF HEMATOLOGY

Regulatory T cells in acute myelogenous leukemia: is it time for immunomodulation?

(2011) C. Ustun et al.   BLOOD

Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor

(2011) M. S. Redell et al.   BLOOD

Is silence still golden? Mapping the RNAi patent landscape

(2011) Per Lundin   NATURE BIOTECHNOLOGY

New Insights into Therapeutic Targets in Myeloma

(2011) K. C. Anderson   Hematology-American Society of Hematology Education Program

FLT3 as a therapeutic target in AML: still challenging after all these years

(2010) T. Kindler et al.   BLOOD

Targeting Stat3 in the Myeloid Compartment Drastically Improves the In vivo Antitumor Functions of Adoptively Transferred T Cells

(2010) A. Herrmann et al.   CANCER RESEARCH

MicroRNA Biogenesis Is Required for Myc-Induced B-Cell Lymphoma Development and Survival

(2010) M. P. Arrate et al.   CANCER RESEARCH

Cell-specific expression of TLR9 isoforms in inflammation

(2010) Kelly J. McKelvey et al.   JOURNAL OF AUTOIMMUNITY

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors

(2010) Heehyoung Lee et al.   NATURE MEDICINE

Soluble Polymer Carriers for the Treatment of Cancer: The Importance of Molecular Architecture

(2009) Megan E. Fox et al.   ACCOUNTS OF CHEMICAL RESEARCH

Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet

(2009) H. Dohner et al.   BLOOD

Toll-like Receptors (TLRs) are expressed by myeloid leukaemia cell lines, but fail to trigger differentiation in response to the respective TLR ligands

(2009) Masashi Okamoto et al.   BRITISH JOURNAL OF HAEMATOLOGY

Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target

(2009) Dharminder Chauhan et al.   CANCER CELL

Toll-like Receptor 9 Activation of Signal Transducer and Activator of Transcription 3 Constrains Its Agonist-Based Immunotherapy

(2009) M. Kortylewski et al.   CANCER RESEARCH

A threshold level of TLR9 mRNA predicts cellular responsiveness to CpG-ODN in haematological and non-haematological tumour cell lines

(2009) Areej Assaf et al.   CELLULAR IMMUNOLOGY

Targeting Signal Transducer and Activator of Transcription Signaling Pathway in Leukemias

(2009) Mustafa Benekli et al.   JOURNAL OF CLINICAL ONCOLOGY

The role of Toll-like receptors in chronic B cell malignancies

(2009) Marta Muzio et al.   LEUKEMIA & LYMPHOMA

Dicer and outcomes in patients with acute myeloid leukemia (AML)

(2009) Mike G. Martin et al.   LEUKEMIA RESEARCH

The promises and pitfalls of RNA-interference-based therapeutics

(2009) Daniela Castanotto et al.   NATURE

In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses

(2009) Marcin Kortylewski et al.   NATURE BIOTECHNOLOGY

siRNA and Innate Immunity

(2009) Marjorie Robbins et al.   OLIGONUCLEOTIDES

Therapeutic Applications of DNA and RNA Aptamers

(2009) Kristina W. Thiel et al.   OLIGONUCLEOTIDES

STAT3 as a target for inducing apoptosis in solid and hematological tumors

(2008) Khandaker Al Zaid Siddiquee et al.   CELL RESEARCH

Obstacles to effective Toll-like receptor agonist therapy for hematologic malignancies

(2008) D E Spaner et al.   ONCOGENE

TLR signaling by tumor and immune cells: a double-edged sword

(2008) B Huang et al.   ONCOGENE